Article
Oncology
Yushan Jia, Shuai Quan, Jialiang Ren, Hui Wu, Aishi Liu, Yang Gao, Fene Hao, Zhenxing Yang, Tong Zhang, He Hu
Summary: This study assessed the predictive value of magnetic resonance imaging (MRI) radiomics for progression-free survival (PFS) in patients with prostate cancer (PCa). The results showed that the hybrid model constructed from radiomics and clinical data performed the best in predicting PFS. This model provides a non-invasive diagnostic tool for risk stratification of clinical patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Gaohaer Kadeerhan, Bo Xue, Xiaolin Wu, Xiaofeng Hu, Jun Tian, Dongwen Wang
Summary: In this study, a robust 8-gene signature was established based on transcriptome profiles of prostate cancer for accurately predicting the risk of biochemical recurrence. PRAME, a risk-related gene, was found to be upregulated in high-risk prostate cancer samples and correlated with chemotherapeutic drug response. Knocking down PRAME reduced the proliferation, migration, and invasion of prostate cancer cells. This study provides a novel tool for stratifying high-risk prostate cancer patients and sheds light on the mechanism of prostate cancer progression.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Oncology
Ying Hou, Ke-Wen Jiang, Li-Li Wang, Rui Zhi, Mei-Ling Bao, Qiao Li, Jing Zhang, Jin-Rong Qu, Fei-Peng Zhu, Yu-Dong Zhang
Summary: AI-aided iBCR-Net using high-throughput MRI can accurately predict biochemical recurrence of prostate cancer after prostatectomy, potentially providing an alternative method for risk stratification of prostate cancer.
BRITISH JOURNAL OF CANCER
(2023)
Article
Genetics & Heredity
Laura Boldrini, Massimo Bardi
Summary: Prostate cancer is a polygenic disease with complex gene-gene interactions. This study found that dysregulation of the WSB1 gene is associated with tumor progression in prostate cancer, as it can lead to abnormal activation of targeted oncogenes. High expression of WSB1 is also correlated with poor prognosis and is closely related to other key genes involved in prostate cancer progression.
Article
Medicine, General & Internal
Gregory S. Alexander, Rebecca F. Krc, James W. Assif, Kai Sun, Jason K. Molitoris, Phuoc Tran, Zaker Rana, Soren M. Bentzen, Mark V. Mishra
Summary: This study analyzed the conditional risks of biochemical failure and prostate cancer-specific death in patients with low- and intermediate-risk prostate cancer treated with external-beam radiotherapy. The study found that the risks of biochemical failure and prostate cancer death increased over time for patients with low- and intermediate-risk prostate cancer.
Review
Medicine, General & Internal
Omar Fahmy, Nabil A. Alhakamy, Waleed Y. Rizg, Alaa Bagalagel, Abdulmohsin J. Alamoudi, Hibah M. Aldawsari, Aiah M. Khateb, Basmah M. Eldakhakhny, Usama A. Fahmy, Wesam H. Abdulaal, Claudia G. Fresta, Giuseppe Caruso
Summary: Understanding the mechanisms underlying the development and progression of prostate cancer is crucial for maximizing the benefit of current medications and guiding future research for targeted therapy. Future treatment strategies may involve predictive genetic and biomarker analysis to assign patients to the most appropriate and effective treatment.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Qiang Su, Zhenyu Liu, Chi Chen, Han Gao, Yongbei Zhu, Liusu Wang, Meiqing Pan, Jiangang Liu, Xin Yang, Jie Tian
Summary: This study evaluated the predictive value of gene signatures for predicting biochemical recurrence in primary prostate cancer patients. Through training and validation sets, a risk score system was established and a prognostic model was plotted for clinical application.
Article
Multidisciplinary Sciences
Jose Francisco Suarez, Victor Zamora, Olatz Garin, Cristina Gutierrez, Angels Pont, Yolanda Pardo, Alai Goni, Alfonso Marino, Asuncion Hervas, Ismael Herruzo, Patricia Cabrera, Gemma Sancho, Javier Ponce de Leon, Victor Macias, Ferran Guedea, Francesc Vigues, Manuel Castells, Montse Ferrer
Summary: This study compared the effectiveness of radical prostatectomy, brachytherapy, and external radiotherapy at ten years of follow-up. The findings showed that brachytherapy and external radiotherapy were not associated with decreased overall survival but had higher risk of biochemical recurrence compared to radical prostatectomy. External radiotherapy also had higher prostate cancer-specific mortality. These results provide valuable information for clinical decision-making.
SCIENTIFIC REPORTS
(2022)
Article
Public, Environmental & Occupational Health
Andri Wilberg Orrason, Hans Garmo, Johan Styrke, Paul W. Dickman, Par Stattin
Summary: Net survival, measured in different frameworks, such as relative survival and cause-specific survival, was compared in men with prostate cancer. The study found biases in estimates of survival rates for different age groups and risk categories, emphasizing the importance of evaluating underlying assumptions for each method.
AMERICAN JOURNAL OF EPIDEMIOLOGY
(2021)
Article
Oncology
Rui Zhou, Yuanfa Feng, Jianheng Ye, Zhaodong Han, Yuxiang Liang, Qingbiao Chen, Xiaoming Xu, Yuhan Huang, Zhenyu Jia, Weide Zhong
Summary: This study analyzed gene expression in tumor-adjacent normal tissues and identified a 10-gene prognostic model that accurately predicts biochemical recurrence-free survival in prostate cancer patients. The predictive ability was validated using an independent cohort. The prognostic genes in the tumor microenvironment were enriched in the p53 signaling pathway, indicating potential crosstalk mechanisms between tumor and its microenvironment in prostate cancer progression.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Tae Hyung Kim, Jason Joon Bock Lee, Jaeho Cho
Summary: Our study investigated the clinical features of PSA bounce in patients undergoing brachytherapy. PSA bounce is common and distinguishing between large bounces and biochemical failures is challenging. The results showed that age, the PSA nadir value at 2 years, and prostate volume were significant factors for PSA bounce.
Article
Biochemistry & Molecular Biology
Ivana Samarzija, Pasko Konjevoda
Summary: Prostate cancer is a heterogeneous disease with unpredictable course, and the search for biomarkers to guide treatment options is crucial. In this study, we analyzed the expression of ECM- and IACs-related genes in prostate cancer using The Cancer Genome Atlas data, and found that they are potential biomarkers for predicting progression-free survival of patients stratified by Gleason score. Specifically, low expression of FMOD and high expression of PTPN2 genes are associated with worse survival in patients with Gleason score lower than 9. Our findings suggest potential biomarkers for prostate cancer progression.
Article
Oncology
Alicia C. McDonald, Jeremy Gernand, Nathaniel R. Geyer, Hongke Wu, Yanxu Yang, Ming Wang
Summary: The study found that higher ambient air concentrations of arsenic and cadmium were associated with lower overall and prostate cancer-specific survival among prostate cancer cases. These associations were observed in the total population and stratified by geographical region. Reducing exposure to arsenic and cadmium could potentially decrease prostate cancer deaths.
Article
Oncology
William Lautert-Dutra, Camila M. Melo, Luiz P. Chaves, Francisco C. Souza, Cheryl Crozier, Adam E. Sundby, Elizabeth Woroszchuk, Fabiano P. Saggioro, Filipe S. Avante, Rodolfo B. dos Reis, Jeremy A. Squire, Jane Bayani
Summary: The diverse clinical outcomes of prostate cancer have led to the development of gene signature assays predicting disease progression. Improved prostate cancer progression biomarkers are needed as current RNA biomarker tests have varying success for intermediate prostate cancer. Interest grows in universal gene signatures for invasive carcinoma progression.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Michelle S. Chen, Lauren E. Howard, Shannon Stock, Anna Dolgner, Stephen J. Freedland, William Aronson, Martha Terris, Zachary Klaassen, Christopher Kane, Christopher Amling, Matthew Cooperberg, Timothy J. Daskivich
Summary: The study aimed to validate the Prostate Cancer Comorbidity Index (PCCI) score in predicting other-cause mortality (OCM) and cancer outcomes in prostate cancer patients receiving hormone therapy. Through follow-up and assessment of 4857 patients, the study found that higher PCCI scores were associated with increased risk of OCM and worse cancer outcomes.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)